IP Library Patent Application 15557637
Patent Application
App. No. 15/557,637

Fentanyl Transdermal Delivery System

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/557,637
Abstract

Described is a transdermal device comprising a backing layer; an adhesive matrix comprising fentanyl as an active agent suspended on a plurality of pressure sensitive adhesives along with a cross-linked moisture absorbent comprising cross-linked polyvinylpyrrolidone; and a release layer. Also described is a method of relieving pain, which comprising applying said transdermal device to the skin of a patient in need thereof.

Claims (32)

1 . A transdermal delivery system comprising:

a backing layer;

an adhesive matrix comprising fentanyl, an analgetically effective relative of fentanyl, or mixtures thereof, a plurality of pressure sensitive adhesives selected from a silicone adhesive, a polyacrylate adhesive, and combinations thereof, and a cross-linked moisture absorbent comprising cross-linked polyvinylpyrrolidone; and

a release liner.

2 . The transdermal delivery system of claim 1 , wherein the fentanyl comprises crystals having a particle size (d 50 ) in a range of about 5 to 20 microns as measured by laser diffraction.

3 . The transdermal delivery system of claim 2 , wherein the particle size (d 50 ) is in the range of about 10 to about 15 microns.

4 . The transdermal delivery system of claim 1 , wherein the polyacrylate adhesive is present in the adhesive matrix in an amount in a range of about 1.0 to about 4.0% w/w.

5 . The transdermal delivery system of claim 1 , wherein the silicone adhesive is present in the adhesive matrix in an amount in a range of about 80 to about 90% w/w.

6 . The transdermal delivery system of claim 1 , wherein the fentanyl is present in the adhesive matrix in an amount in a range of about 3 to about 5% w/w.

7 . The transdermal delivery system of claim 1 , wherein the cross-linked polyvinylpyrrolidone is present in the adhesive matrix in an amount in a range of about 2 to about 6% w/w.

8 . The transdermal delivery system of claim 1 , wherein the silicone adhesive further comprises a silicone medical fluid.

9 . The transdermal delivery system of claim 8 , wherein the silicone medical fluid comprises dimethicone.

10 . The transdermal delivery system of claim 9 , wherein the dimethicone is present in the adhesive matrix in an amount in a range of about 2 to about 7% w/w.

11 . The transdermal delivery system of claim 1 , wherein the release liner comprises one or more of paper, coated paper, plastic films, polyolefins made of high density polyethylene (HDPE), low density polyethylene (LDPE), polypropylene (PP) plastic resin, fluoropolymer-coated films.

12 . The transdermal delivery system of claim 11 , wherein the release liner comprises LDPE.

13 . The transdermal delivery system of claim 11 , wherein the release liner comprises a fluoropolymer-coated polyethylene terephthalate (PET) film.

14 . The transdermal delivery system of claim 1 , wherein the backing layer comprises films of polyethylene, polyethylene terephthalate (PET), polypropylene, polyurethane, ethylene vinyl acetate (EVA) of polyamide, metal foils, or paper, alone or coated with a polymeric material, or mixtures thereof.

15 . The transdermal delivery system of claim 14 , wherein the backing layer comprises a PET-EVA laminate.

16 . The transdermal delivery system of claim 1 , wherein the backing layer has a thickness of less than about 2.5 mil.

17 . The transdermal delivery system of claim 1 , wherein the transdermal delivery system has reduced cold flow when compared to transdermal delivery systems that do not contain cross-linked polyvinylpyrrolidone.

18 . The transdermal delivery system of claim 1 , wherein the transdermal delivery system has skin flux in a range of about 2 to about 6 mcg/cm 2 /h.

19 . A transdermal delivery system comprising:

a backing layer;

an adhesive matrix comprising:

3.5 to 4.5% w/w fentanyl,

80 to 90% w/w silicone adhesive,

1 to 4% w/w polyacrylate adhesive, and

2 to 6% w/w cross-linked polyvinylpyrrolidone; and

a release liner.

20 . The transdermal delivery system of claim 19 , the adhesive matrix further comprising 2 to 7% w/w silicone medical fluid.

21 . A method of relieving pain comprising: applying to skin of a patient in need thereof the transdermal delivery system of claim 1 .

22 . A method of relieving pain comprising: applying to skin of a patient in need thereof the transdermal delivery system of claim 19 .

Assignments (3)
RELEASE OF SECURITY INTEREST IN PATENTS AT R/F 060050/0224 Recorded Jan 21, 2025
From: JPMORGAN CHASE BANK, N.A., AS AGENT
To: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC
Reel/Frame 069958/0509 →
PATENT SECURITY AGREEMENT (TERM LOAN) Recorded May 12, 2022
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 060050/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2018
From: AUDETT, JAY; WON, CHEE YOUB
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 045182/0161 →